ARTICLE SUMMARY:
Boston Scientific’s $1.07 billion acquisition of the surgical laser company Lumenis is pricey for a tuck-in, but the deal nets it far more than a market-leading product in a high-growth category.
Meghan Scanlon, president of the Urology and Pelvic Health division of Boston Scientific Corp., calls her company’s recent acquisition of the global surgical business of Israeli laser company Lumenis Ltd. “a perfect marriage.” The deal, which closed in September, unites a leader in laser surgery for kidney stones with the world leader in devices for prostate health.
